$7.65
+3.7%DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Chief Commercial Officer
Compensation
$415,678
Chief Compliance Officer
Chief Executive Officer & Director
Compensation
$618,084
Chief Financial Officer, Treasurer & Secretary
Compensation
$414,455
Chief Operations Officer
Chief People Officer
Chief Technology Officer
Compensation
$476,881
Co-Founder & Production Chief
Content & Communications Manager
Investor Relations Manager
During the last 12 months, insiders have purchased $21K worth of DRIO shares, with no selling activity reported.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
40.0K
21.20K
0
0.00
+21K
+$21K
Nelson Steven Charles
Officer: President And Cco
$21K
No selling activity
Strong bullish signal with $21K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.
DRIO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | December 22, 2025 | January 29, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | May 30, 2025 | July 23, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | March 10, 2025 | April 28, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | October 24, 2024 | December 18, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | May 01, 2024 | June 25, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | October 26, 2023 | December 11, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | October 14, 2022 | December 07, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 26, 2021 | June 07, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | September 02, 2020 | October 14, 2020 | 2020 | |
DEF 14A DEF 14A 2020 N/A | December 27, 2019 | February 05, 2020 | 2020 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.